Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Patients With Renal Cell Carcinoma and Melanoma Metastatic to the Brain
NCT00462982Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2007
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in renal cell carcinoma (RCC) and melanoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Central Nervous System (CNS) Response Rate by RECIST Criteria. Started Mar 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)melanoma
Beyond the preview
Go deeper on NCT00462982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00462982.